Eton Pharmaceuticals, Inc.
NASDAQ:ETONBiotechnology
-$0.46 today
- Market cap
- $1.79B
- Beta
- 0.89
- P/E (TTM)
- -597.6
- EPS (TTM)
- -$0.05
Volume 0.48M
Average 0.43M
ETON Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Eton Pharmaceuticals, Inc.NASDAQ: ETON
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity rises 25.2% from a year ago
Total equity stood at $30.62M at the end of Q1 FY2026, up 25.2% from a year earlier and up 17.1% from the prior quarter. Over 3 fiscal years it compounded at +26.0% a year.
Context
- Total equity amounted to 31.3% of total assets at the end of Q1 FY2026, up 2.2 pp from a year earlier.
- Total equity increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps rising in the next quarterly balance sheet after a +25.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 26.15M USD
- Year-over-year change
- +7.1%
- 4-year CAGR
- +10.4%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 26.15M | +7.1% |
| FY2024 | 2024-12-31 | 24.43M | +57.8% |
| FY2023 | 2023-12-31 | 15.48M | +18.3% |
| FY2022 | 2022-12-31 | 13.08M | -25.8% |
| FY2021 | 2021-12-31 | 17.63M | — |
Total Equity vs competitors
How ETON compares with its peers on the latest reported figures
- ETON's Mar 2026 total equity of $30.62M is the 8th highest of the 10 companies compared; the peer median is $158.03M.
- Its year-over-year change of +25.2% is the 5th highest of 10, against a peer median of +24.9%.
- Total equity amounts to 31.3% of total assets for ETON, versus a peer median of 55.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $393.64M | -36.3% | -5.1% | 13.5% | |
| Mar 2026 | $268.96M | +24.9% | +10.6% | 55.0% | |
| Mar 2026 | $205.8M | +401.7% | +27.2% | 73.9% | |
| Mar 2026 | $202.86M | +64.9% | -2.8% | 75.5% | |
| Mar 2026 | $158.03M | +9.5% | -11.0% | 75.8% | |
| Mar 2026 | $47.24M | +39.1% | +20.8% | 89.0% | |
| Mar 2026 | $37.68M | +740.7% | — | 52.5% | |
| Mar 2026 | $30.62M | +25.2% | +26.0% | 31.3% | |
| Sep 2026 | $22.58M | -69.3% | +38.9% | 2.7% | |
| Mar 2026 | -$229M | -251.4% | — | 17.7% | |
| Peer median (excluding ETON) | $158.03M | +24.9% | +10.6% | 55.0% | |
Competitors are the stored peer set for ETON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 14.41M | 16.31M | 21.39M | 14.94M | 25.94M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 5.47M | 1.85M | 3.41M | 5.36M | 11.76M |
| Inventory | 550K | 557K | 911K | 15.23M | 15.42M |
| Other Current Assets | 0 | 1.29M | 0 | 5.49M | 7.46M |
| Total Current Assets | 23.6M | 20M | 26.84M | 41.02M | 60.58M |
| Property, Plant & Equipment (Net) | 219K | 260K | 150K | 209K | 636K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 3.62M | 4.75M | 4.74M | 34.88M | 30.88M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 21K | 12K | 12K | 12K | 19K |
| Total Non-current Assets | 3.86M | 5.03M | 4.9M | 35.1M | 31.53M |
| Total Assets | 27.47M | 25.03M | 31.74M | 76.12M | 92.11M |
| Account Payables | 1.77M | 1.77M | 1.85M | 4.17M | 10.98M |
| Short-term Debt | 1.42M | 1.03M | 5.38M | 76K | 8.79M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 15.66M | 0 |
| Total Current Liabilities | 4.56M | 6.46M | 16.24M | 19.95M | 38.49M |
| Long-term Debt | 5.26M | 5.38M | 0 | 29.81M | 21.77M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 1.76M |
| Other Non-current Liabilities | 0 | 0 | 0 | 1.83M | 3.48M |
| Total Non-current Liabilities | 5.28M | 5.49M | 22K | 31.75M | 27.47M |
| Total Liabilities | 9.84M | 11.95M | 16.26M | 51.7M | 65.96M |
| Common Stock | 25K | 25K | 26K | 27K | 27K |
| Retained Earnings | (94.11M) | (103.13M) | (104.07M) | (107.89M) | (112.49M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 17.63M | 13.08M | 15.48M | 24.43M | 26.15M |
| Total Debt | 6.7M | 6.52M | 5.4M | 29.99M | 31.02M |
| Net Debt | (7.71M) | (9.78M) | (15.99M) | 15.06M | 5.08M |
Eton Pharmaceuticals, Inc.
NASDAQ:ETON
Intrinsic Alpha fair value
Locked
Current Price
$61.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.